glp 1 for metabolic syndrome Resmetirom and GLP-1 agonists MASH: complementary rather than exclusive Possible mechanisms of the interaction
Description
Commercial plans like Blue Cross Blue Shield of Massachusetts plan to eliminate coverage of GLP-1s for weight loss in 2026 in response to high drug costs and their effect on insurance premiums
Shuster, L
[DOI] [PubMed] [Google Scholar] 160.Sun T., Xu W., Wang J., Wang T., Wang S., Liu K., Liu J
Combined with medical supervision, these treatments address the root causes of weight gain
Mounjaro: Mounjaro is FDA-approved for type 2 diabetes
Compensated for usage rights
